Abstract: The present invention relates to a conversion device for converting a treatment beam for treating a lesion of a subject, comprising: a collimator unit to which the treatment beam is incident and which has a plurality of slits; and a scattering unit that scatters the treatment beam that has passed through the collimator unit.

Abstract: Provided is an adhesive composition, an adhesive product, and a method of preparing an adhesive composition. The adhesive composition including lysine, oxaloacetic acid, and water, wherein the lysine and the oxaloacetic acid are present in the form of an aqueous salt solution and do not form precipitates in the aqueous solution.

Abstract: Provided is an adhesive composition including lysine, malic acid, and water, wherein the lysine and the malic acid are present in the form of an aqueous salt solution and do not form precipitates in the aqueous solution.

Abstract: An anode for a lithium secondary battery includes an anode current collector, a second anode active material layer disposed on the anode current collector and including a second anode active material that includes a graphite-based active material and composite particles, and a first anode active material layer disposed between the anode current collector and the second anode active material layer and including a first anode active material that includes a graphite-based active material and does not include the composite particles. Each of the composite particles includes a carbon-based particle including pores, a silicon-containing coating layer disposed on an inside of the pores of the carbon-based particle or on a surface of the carbon-based particle, and a surface oxide layer disposed on the silicon-containing coating layer and including a silicon oxide.

Abstract: A pixel including: a light emitting element; a first transistor connected between a first node and a second node, and to generate a driving current to flow from a first power line to a second power line through the light emitting element; a second transistor connected between a data line and the first node; a third transistor connected between the second node and a third node corresponding to a gate electrode of the first transistor; a fourth transistor connected between the third node and a third power line; a fifth transistor connected between the first power line and the first node; a sixth transistor connected between the second node and a fourth node corresponding to a first electrode of the light emitting element; a seventh transistor connected between the fourth node and a fourth power line; and an eighth transistor connected between the fourth node and a fifth power line.

Abstract: The present invention relates to a method for determining the DNA quality of a biological sample and, more specifically, to a method for determining the DNA quality of a biological sample by performing a quantitative polymerase chain reaction (PCR) using primers capable of amplifying a target gene, a method for preparing the primers used in the method, and a method for standardizing the amount of detected target gene mutation by using the determined DNA quality. The method of the present invention enables objective evaluation of the DNA quality of a biological sample used in gene analysis and the presentation of objective results on the expression ratio of a gene mutation, thereby providing reliable information in the fields of clinical research and companion diagnosis.

Abstract: The present invention relates to a composition, a kit, a nucleic acid chip and a method which allow the diagnosis of liver cancer by detecting methylation levels of CpG sites of any one or more genes selected from the group consisting of FAM110A, FAR1, VIM, LDHB, LIPE, INAFM1, ATL1, CELF6, MTHFD2, PAK1, NXPE3, SLC25A36 and VANGL2. The present invention enables accurate and rapid diagnosis of liver cancer, and also enables early diagnosis.

Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.

Abstract: The present invention relates to a composition, a kit, a nucleic acid chip and a method, for diagnosing colorectal cancer, rectal cancer or colorectal adenoma by detecting the methylation level of CpG sites in a LINC01798 gene, in which colorectal cancer, rectal cancer, or colorectal adenoma can not only be diagnosed accurately and rapidly, but can also be diagnosed early.

Abstract: The present invention relates to a composition, a kit, a nucleic acid chip, and a method capable of diagnosing colorectal cancer, rectal cancer, or colorectal adenoma by detecting the methylation level of CpG sites in a GLRB gene. Accordingly, colorectal cancer, rectal cancer, or colorectal adenoma can be diagnosed not only accurately and quickly, but also at an early stage.

Abstract: The present invention relates to a composition, a kit, a nucleic acid, and a method capable of diagnosing bladder cancer by detecting the methylation level of a CpG site of at least one gene selected from the group consisting of IFFO1, MARCH11, BARHL2, NR2E1, KCNA3, and BOLL. According to the present invention, since the hypermethylation of a CpG site of a gene is specifically exhibited in bladder cancer, a composition, a kit, a chip, or a method according to the present invention can be used to accurately and rapidly diagnose bladder cancer and to be used for early diagnosis and monitoring recurrence.

Abstract: A method for the synthesis of a compound of Formula II is provided. Also disclosed is the salt form of the compound. The method includes the introduction of a piperidinyl moiety in a polar aprotic solvent system, followed by the removal of the protecting group and the acrylation step.

Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy. Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.

Abstract: The present invention relates to a method for detecting lung cancer using a lung cancer-specific biomarker, and more particularly to a biomarker for lung cancer diagnosis, which can detect methylation of PCDHGA12 gene whose 5?UTR or exon 1 region is specifically methylated in lung cancer cells, and to a method of detecting lung cancer and the stage of its progression using the biomarker. The diagnostic kit according to the present invention makes it possible to diagnose lung cancer at an early stage in an accurate and rapid manner compared to conventional methods and can be used for prognosis and monitoring of lung cancer and the stage of its progression.

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy. Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient, and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.

Abstract: The present invention relates to a method for determining the DNA quality of a biological sample and, more specifically, to a method for determining the DNA quality of a biological sample by performing a quantitative polymerase chain reaction (PCR) using primers capable of amplifying a target gene, a method for preparing the primers used in the method, and a method for standardizing the amount of detected target gene mutation by using the determined DNA quality. The method of the present invention enables objective evaluation of the NDA quality of a biological sample used in gene analysis and the presentation of objective results on the expression ratio of a gene mutation, thereby providing reliable information in the fields of clinical research and companion diagnosis.

Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.

Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.

Abstract: The present disclosure relates to a method for detecting CpG methylation of SDC2 (Syndecan 2) gene, a kit for detecting CpG methylation of SDC2 (Syndecan 2) gene, and a method for detecting CpG methylation of SDC2 (Syndecan 2) gene for a colorectal cancer diagnosis.